Archives of Neuroscience

Published by: Kowsar

Tissue Plasminogen Activator: A Literature Review

Alireza Baratloo 1 , Mohammad Mehdi Forouzanfar 1 , * , Behrooz Hashemi 1 , Saeed Safari 1 , Hosein Delavar Kasmaei 2 , Alaleh Rouhipour 3 and Ahmed Negida 4
Authors Information
1 Department of Emergency Medicine, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Neurology, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Pediatric, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Faculty of Medicine, Zagazig University, Zagazig, Egypt
Article information
  • Archives of Neuroscience: January 01, 2016, 3 (1); e30452
  • Published Online: January 16, 2016
  • Article Type: Review Article
  • Received: June 1, 2015
  • Accepted: July 13, 2015
  • DOI: 10.5812/archneurosci.30452

To Cite: Baratloo A, Forouzanfar M M, Hashemi B, Safari S, Delavar Kasmaei H, et al. Tissue Plasminogen Activator: A Literature Review, Arch Neurosci. 2016 ; 3(1):e30452. doi: 10.5812/archneurosci.30452.

Abstract
Copyright © 2016, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnote
References
  • 1. Rother J, Ford GA, Thijs VN. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. Cerebrovasc Dis. 2013; 35(4): 313-9[DOI][PubMed]
  • 2. Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost. 2004; 2(4): 541-6[DOI][PubMed]
  • 3. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981; 256(13): 7035-41[PubMed]
  • 4. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study I. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172(10): 1307-12[DOI][PubMed]
  • 5. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984; 310(10): 609-13[DOI][PubMed]
  • 6. Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Seminars in thrombosis and hemostasis. : 236-41
  • 7. Mullen MT, Pisapia JM, Tilwa S, Messé SR, Stein SC. Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+ intra-arterial thrombolysis. Stroke. 2012; 43(9): 2350-5
  • 8. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995; 92(10): 3032-40[PubMed]
  • 9. Mehrpour M, Aghaei M, Motamed MR. Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke. Med J Islam Repub Iran. 2013; 27(3): 113-8[PubMed]
  • 10. Davami F, Sardari S, Majidzadeh AK, Hemayatkar M, Barkhordari F, Enayati S, et al. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments. BMB Rep. 2011; 44(1): 34-9[DOI][PubMed]
  • 11. Syed MI, Shaikh A, Ullah A, Akhter TS, Ranginwala S, Mohammed MI, et al. Acute renal artery thrombosis treated with t-PA power-pulse spray rheolytic thrombectomy. Cardiovasc Revasc Med. 2010; 11(4): 264. e1-7
  • 12. Niwa J, Ohyama H, Matumura S, Maeda Y, Shimizu T. Treatment of acute superior sagittal sinus thrombosis by t-PA infusion via venography--direct thrombolytic therapy in the acute phase. Surg Neurol. 1998; 49(4): 425-9[PubMed]
  • 13. Baratloo A, Safari S, Rouhipour A, Hashemi B, Rahmati F, Motamedi M, et al. The Risk of Venous Thromboembolism with Different Generation of Oral Contraceptives; a Systematic Review and Meta-Analysis. Emergency. 2014; 2(1): 1-11
  • 14. Kasmaei HD, Baratloo A, Nasiri Z, Soleymani M, Shirafkan A, Hamedi ZS. Report of Nineteen Cerebral Vein Thrombosis Referrals to an Emergency Department: a Case Series and Literature Review. Arch Neurosci. 2015; 2(2)
  • 15. Delavar Kasmaei H, Baratloo A, Soleymani M. A 33-year-old woman with severe postpartum headache. Emergency. 2013; 1(1): 27-9
  • 16. Briosa ED, Almeida A, Monteiro N, Paiva Nunes A, Ferreira P, Mendonca N, et al. Successful Thrombolysis despite Having an Incidental Unruptured Cerebral Aneurysm. Case Rep Neurol Med. 2014; 2014: 323049[DOI][PubMed]
  • 17. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke. 2011; 42(8): 2257-62[DOI][PubMed]
  • 18. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998; 50(4): 883-90[PubMed]
  • 19. Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke. 2007; 38(1): 85-9[DOI][PubMed]
  • 20. Delavar Kasmaei H, Baratloo A, Nasiri Z, Soleymani M, Oraee Yazdani M. Recombinant Tissue Plasminogen Activator Administration in Patients With Cerebrovascular Accident; A Case Series. Arch Neurosci. 2015; 2(2)
  • 21. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000; 31(4): 811-6[PubMed]
  • 22. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21): 2019-26[PubMed]
  • 23. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000; 55(11): 1649-55[PubMed]
  • 24. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13): 1017-25[PubMed]
  • 25. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136): 1245-51[PubMed]
  • 26. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317-29[DOI][PubMed]
  • 27. DeMers G, Meurer WJ, Shih R, Rosenbaum S, Vilke GM. Tissue plasminogen activator and stroke: review of the literature for the clinician. J Emerg Med. 2012; 43(6): 1149-54[DOI][PubMed]
  • 28. del Zoppo GJ, Saver JL, Jauch EC, Adams HP. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40(8): 2945-8
  • 29. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010; 9(9): 866-74[DOI][PubMed]
  • 30. Xu ZP, Li HH, Li YH, Zhang Y, Wu Q, Lin L. Feasibility and outcomes of intravenous thrombolysis 3-4.5 hours after stroke in Chinese patients. J Clin Neurosci. 2014; 21(5): 822-6[DOI][PubMed]
  • 31. Tekle WG, Chaudhry SA, Hassan AE, Peacock JM, Lakshminarayan K, Tsai A, et al. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry. Cerebrovasc Dis. 2012; 34(5-6): 400-5[DOI][PubMed]
  • 32. Shobha N, Buchan AM, Hill MD, Canadian Alteplase for Stroke Effectiveness S. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis. 2011; 31(3): 223-8[DOI][PubMed]
  • 33. Burnette WC, Nesbit GM. Intra-arterial thrombolysis for acute ischemic stroke. Eur Radiol. 2001; 11(4): 626-34[DOI][PubMed]
  • 34. Mar J, Arrospide A, Comas M. Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model. Value Health. 2010; 13(1): 69-76[DOI][PubMed]
  • 35. Fattahi A, Azad A, Montazeri A. Quality of life among stroke patients in kermanshah city. Mod Rehabil. 2008; 2(1): 1-8
  • 36. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke. 2005; 36(1): 62-5[DOI][PubMed]
  • 37. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000; 283(9): 1151-8[PubMed]
  • 38. Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat. 2011; 2011: 686797[DOI][PubMed]
  • 39. Aiyagari V, Gujjar A, Zazulia AR, Diringer MN. Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it? Stroke. 2004; 35(10): 2326-30[DOI][PubMed]
  • 40. Hsieh CY, Chen CH, Chen YC, Kao Yang YH. National survey of thrombolytic therapy for acute ischemic stroke in Taiwan 2003-2010. J Stroke Cerebrovasc Dis. 2013; 22(8)-7[DOI][PubMed]
  • 41. Nandigam K, Narayan SK, Elangovan S, Dutta TK, Sethuraman KR, Das AK. Feasibility of acute thrombolytic therapy for stroke. Neurol India. 2003; 51(4): 470-3[PubMed]
  • 42. de Villiers L, Kalula SZ, Burch VC. Does multidisciplinary stroke care improve outcome in a secondary-level hospital in South Africa? Int J Stroke. 2009; 4(2): 89-93[DOI][PubMed]
  • 43. Bryer A, Wasserman S. Thrombolysis for acute ischemic stroke in South Africa. Int J Stroke. 2013; 8 Suppl A100: 112-3[DOI][PubMed]
  • 44. Ghandehari K, Zahed AP, Taheri M, Abbasi M, Gorjestani S, Ahmadi AM, et al. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA. Int J Stroke. 2009; 4(4): 236[DOI][PubMed]
  • 45. Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke. 2007; 2(1): 17-26[DOI][PubMed]
  • 46. Ghandehari K, Foroughipour M, Pourzahed A, Taheri M, Abbasi M, Gorjestani S, et al. Thrombolysis in stroke patients; problems and limitations. Iran J Med Sci. 2015; 35(2): 145-8
  • 47. Ghandehari K. Design of a standard Iranian protocol of Intravenous thrombolysis with tissue plasminogen activator: A national project. Iran J Neurol. 2013; 12(2): 72-4[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments